AstraZeneca Takes Next Steps Towards Broad and Equitable Access to Oxford University ’s COVID-19 Vaccine
4 June 2020 -- AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements with the Coalition for Epidemic Preparedness Innovations... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 4, 2020 Category: Pharmaceuticals Source Type: clinical trials
AstraZeneca Advances Response to Global COVID-19 Challenge as it Receives First Commitments for Oxford ’s Potential New Vaccine
21 May 2020 -- AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations to make the University of Oxford’s vaccine widely... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 21, 2020 Category: Pharmaceuticals Source Type: clinical trials
AstraZeneca and Oxford University Announce Landmark Agreement for COVID-19 Vaccine
30 April 2020 -- AstraZeneca and the University of Oxford today announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 30, 2020 Category: Pharmaceuticals Source Type: clinical trials
COmmunity-based Rehabilitation after Knee Arthroplasty (CORKA): statistical analysis plan for a randomised controlled trial
DiscussionThis paper provides details of the planned statistical analyses for this trial and will reduce the risks of outcome reporting bias and data-driven results.Trial registrationISRCTN registry,13517704. Registered on 12 February 2015.Funding/sponsorThe trial is funded by the National Institute for Health Research Health Technology Assessment programme under its commissioned research programme (HTA 12/196/08). The trial sponsor is the University of Oxford. (Source: Trials)
Source: Trials - November 19, 2018 Category: Research Source Type: clinical trials
A protocol for the process evaluation of a multi-centre randomised trial to compare the effectiveness of geriatrician-led admission avoidance hospital at home versus inpatient admission
DiscussionThis process evaluation will enable evaluation of implementation processes prior to knowing trial outcomes. We encompass domains of reach, delivery, change, context and response to the intervention by patients, their carers, health professionals and the health system.Trial registrationISRCTN60477865. Registered on 10 March 2014. Trial sponsor: University of Oxford.Version 3.1, registered on 14 June 2016. (Source: Trials)
Source: Trials - October 19, 2018 Category: Research Source Type: clinical trials
EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
Condition: Chronic Kidney Disease Interventions: Drug: Empagliflozin; Drug: Matching placebo Sponsors: Boehringer Ingelheim; Medical Research Council Population Health Research Unit, CTSU, University of Oxford (academic lead); Eli Lilly and Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 20, 2018 Category: Research Source Type: clinical trials
